Abstract

BackgroundThe R47H variant of the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) significantly increases the risk for late onset Alzheimer’s disease. Mouse models accurately reproducing phenotypes observed in Alzheimer’ disease patients carrying the R47H coding variant are required to understand the TREM2 related dysfunctions responsible for the enhanced risk for late onset Alzheimer’s disease.MethodsA CRISPR/Cas9-assisted gene targeting strategy was used to generate Trem2 R47H knock-in mice. Trem2 mRNA and protein levels as well as Trem2 splicing patterns were assessed in these mice, in iPSC-derived human microglia-like cells, and in human brains from Alzheimer’s patients carrying the TREM2 R47H risk factor.ResultsTwo independent Trem2 R47H knock-in mouse models show reduced Trem2 mRNA and protein production. In both mouse models Trem2 haploinsufficiency was due to atypical splicing of mouse Trem2 R47H, which introduced a premature stop codon. Cellular splicing assays using minigene constructs demonstrate that the R47H variant induced abnormal splicing only occurs in mice but not in humans. TREM2 mRNA levels and splicing patterns were both normal in iPSC-derived human microglia-like cells and patient brains with the TREM2 R47H variant.ConclusionsThe Trem2 R47H variant activates a cryptic splice site that generates miss-spliced transcripts leading to Trem2 haploinsufficiency only in mice but not in humans. Since Trem2 R47H related phenotypes are mouse specific and do not occur in humans, humanized TREM2 R47H knock-in mice should be generated to study the cellular consequences caused by the human TREM2 R47H coding variant. Currently described phenotypes of Trem2 R47H knock-in mice can therefore not be translated to humans.

Highlights

  • The R47H variant of the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) significantly increases the risk for late onset Alzheimer’s disease

  • The founder mouse was back-crossed to C57BL/6 N, and off-spring with positive Trem2 R47H ki but negative off-target #2 (i.e ID-7-1; ID-7-2; ID-7-4) were used for establishing the mouse line

  • We found that TREM2 mRNA levels and splicing patterns were both normal in induced pluripotent stem cell (iPSC)-derived human microglia-like cells and in patient brains with the TREM2 R47H variant

Read more

Summary

Introduction

The R47H variant of the Triggering Receptor Expressed on Myeloid cells 2 (TREM2) significantly increases the risk for late onset Alzheimer’s disease. In a study on patients with dominantly inherited AD (DIAN), soluble TREM2 was found to be increased 5 years before onset of clinical symptoms, which may be interpreted as a protective response [15]. Consistent with this conclusion, lack of functional TREM2 affects amyloid plaque morphology and increases plaque associated neuritic dystrophies [13, 16]. In line with findings in mouse models for amyloid plaque pathology, this may be due to stage specific functions of Trem

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call